Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

$191,000 In Grants Awarded By The Society Of Interventional Radiology Foundation
The Society of Interventional Radiology Foundation recently awarded 13 grants totaling more than $191,000 to encourage the development of interventional radiology research. Grant proposals were reviewed during SIR"s 34th Annual Scientific Meeting in San Diego.

'Super-Recognizers,' With Extraordinary Face Recognition Ability, Never Forget A Face
Some people say they never forget a face, a claim now bolstered by psychologists at Harvard University who"ve discovered a group they call "super-recognizers": those who can easily recognize someone they met in passing, even many years later.
News of the day
Hip And Back Fractures Increase Mortality Rates In People Older Than 50
Vertebral and hip fractures are associated with an increased risk of death, found a new study of 7753 people in Canada aged 50 years and older published in CMAJ (Canadian Medical Association Journal). According to the results, approximately 25% of people (both men and women) living in the community who develop a hip fracture and 16% who develop a spine fracture will die over a 5 year period.
Endocrinology

HELP Committee Approves Protection For High Tech Drug Companies From Generics

"Senators agreed Monday to give high-tech biologic drugs 12 years of market protection before generic versions can compete," according to The Associated Press. The AP reports: "The vote in the Senate Health, Education, Labor and Pensions Committee was a victory for the biotechnology and pharmaceutical industries but a defeat for the Obama administration and AARP. The Obama administration had pushed for a seven-year exclusivity period so that patients could get quicker access to cheaper versions of costly medicines used to treat ailments including cancer, Parkinson"s, diabetes and rheumatoid arthritis. Proponents of the longer time frame say products like the blockbuster cancer drug Avastin deserve longer market protection because they are more expensive and time-consuming to produce than regular drugs, and the extra time and money is needed to attract investors and promote innovation. ... The decision would still need agreement from the full Senate and the House, where Energy and Commerce Committee Chairman Henry Waxman, D-Calif., strongly supporters a shorter exclusivity period." The AP notes: "Biotech drugs currently don"t face generic competition because the Food and Drug Administration doesn"t have power to approve copies of such medications. Efforts to change that have been held up for nearly a decade by squabbling between the biotech and generic drug industries and their allies on Capitol Hill" (Werner, 7/14). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009